Fast-Dissociating High-Supply Peptides as Contributors to MHC-I Antigen Presentation.

Om H Gandhi, Michael E Bryan, Malcolm J W Sim, Tim Elliott

Abstract readReview

In one paragraph

Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Om H GandhiCentre for Immuno-Oncology, University of Oxford, Oxford OX3 7DQ, UK.

Michael E BryanCentre for Immuno-Oncology, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0001-8306-009X

Malcolm J W SimCentre for Immuno-Oncology, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0003-3407-9661

Tim ElliottCentre for Immuno-Oncology, University of Oxford, Oxford OX3 7DQ, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The major histocompatibility complex class I (MHC-I) immunopeptidome is dynamic and determined by numerous biochemical and cellular features. Computational tools to predict peptide-MHC-I binding focus on the affinity of a specific peptide-MHC interaction; separate tools predict complex stability or presentation. Methods used to define the immunopeptidome may preferentially recover stable complexes, and presentation predictors trained on those data may inherit that bias. However, peptides that dissociate rapidly but are generated at high rates could reach surface densities sufficient for CD8

Indexed as

Antigen PresentationHistocompatibility Antigens Class IPeptidesAnimalsCD8-Positive T-LymphocytesHumansMembrane Transport ProteinsProtein BindingHistocompatibility Antigens Class IMembrane Transport ProteinsPeptidestapasinantigen presentationdefective ribosomal productsFDHSimmunopeptidomemass spectrometryMHC class Ineoantigenpeptide–MHC stabilitypeptide supplyribosome-associated quality controltapasin

Identifiers

PMID42882433

DOI10.3390/cells15191735

PMCPMC13664392

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.